) is a prescription medication approved to treat adults with type 2 diabetes
. It is used in combination with a diet and exercise plan to improve blood glucose (blood sugar) control. Nesina is not approved for the treatment of type 1 diabetes
or diabetic ketoacidosis (a potentially life-threatening problem that can occur in people with diabetes
), as it will not work for these conditions.
Nesina is a new medicine in the class of medicines known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It was approved by the U.S. Food and Drug Administration (the FDA) in January 2013. Nesina contains the active component alogliptin. Alogliptin is also found in two combination diabetes medicines -- Kazano®
(alogliptin and metformin
) and Oseni®
(alogliptin and pioglitazone
Who Makes This Medication?
Nesina is made by Takeda Pharmaceuticals America, Inc.
Nesina has been studied alone and in combination with certain other diabetes medicines, including metformin
), sulfonylureas, thiazolidinediones
, and insulin
. In these studies, the drug was shown to reduce hemoglobin A1c (HbA1c) and fasting blood glucose in people with type 2 diabetes.
Nesina Effects on Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. People without diabetes and those who have well-controlled diabetes usually have HbA1c results that are less than 6 percent. Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes, such as heart, eye, nerve, and kidney problems.
In one study, people taking Nesina for 26 weeks lowered their HbA1c by 0.6 percent on average, while HbA1c results were unchanged in people taking a placebo (a tablet with no active ingredients). Also, 44 percent of those taking Nesina achieved an HbA1c of 7 or lower after 26 weeks of taking Nesina, compared with only 23 percent of people taking the placebo.
Nesina and Blood Sugar Levels
In studies, people given Nesina had a 16 mg/dL decrease in their fasting blood sugar, on average. In comparison, people given a placebo had an 11 mg/dL increase in their fasting blood sugar, on average.